Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases
Autor: | J. Bayne Selby, Stephan Zangos, Katrin Eichler, Ralf W. Bauer, Thomas J. Vogl |
---|---|
Rok vydání: | 2007 |
Předmět: |
Adult
Male Leiomyosarcoma Oncology Antimetabolites Antineoplastic medicine.medical_specialty Colorectal cancer Mitomycin Breast Neoplasms Deoxycytidine Gastroenterology Cholangiocarcinoma Breast cancer Prostate Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Aged Aged 80 and over Antibiotics Antineoplastic business.industry Liver Neoplasms Palliative Care Mitomycin C Cancer General Medicine Middle Aged medicine.disease Gemcitabine Bile Ducts Intrahepatic Treatment Outcome medicine.anatomical_structure Bile Duct Neoplasms Injections Intra-Arterial Female Radiology Colorectal Neoplasms business medicine.drug |
Zdroj: | European Radiology. 18:468-476 |
ISSN: | 1432-1084 0938-7994 |
Popis: | To evaluate repeated hepatic intraarterial chemotherapy (HIC) as a palliative treatment option for unresectable cholangiocarcinoma and liver metastases of various origins that were progressive under systemic chemotherapy. Between 2002 and 2006, 55 patients were treated in 4-week intervals (mean five sessions). Combined gemcitabine/mitomycin was administered intraarterially within 1 h. Tumor response was evaluated after the third session according to RECIST. Treated tumor entities were colorectal carcinoma (CRC) (n = 12), breast cancer (BC) (n = 12), cholangiocarcinoma (CCC) (n = 10), pancreatic (n = 4), ovarian (n = 3), gastric, cervical, papillary (each n = 2), prostate, esophageal carcinoma, leiomyosarcoma (each n = 1), cancer of unknown primacy (CUP) (n = 5). All patients tolerated the treatment well without any major side effects or complications. In total, there were 1 complete response (CR), 19 partial responses (PR), 19 stable (SD) and 16 progressive diseases (PD). We observed 5 PR, 3 SD and 4 PD in CRC; 1 CR, 4 PR, 6 SD in BC; and 2 PR, 2 SD and 6 PD in CCC. Median survival after first HIC was 9.7 months for CRC, 11.4 months for BC and 6.0 months for CCC. HIC with gemcitabine/mitomycin is a safe, minimally invasive, palliative treatment for hepatic metastases that are progressive under systemic chemotherapy. The treatment yields respectable tumor control rates in CRC and BC patients. |
Databáze: | OpenAIRE |
Externí odkaz: |